CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

Blood Adv · 2026 · PMC13133533 · PMID 41628350

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

12 , 13 , 23 , 40 Although our analysis showed a trend toward improved survival with CPX-351 in this subgroup (median OS, 56.4 vs 17.1 months; HR, 0.32), the limited sample size precludes definitive conclusions regarding the optimal induction regimen for these patients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.